Supplemental Table S2. AEs.

Published: 28 February 2024| Version 1 | DOI: 10.17632/6dvgzt2jmd.1
Contributor:
Hanwen Wu

Description

AE, adverse event; CK, creatine kinase; JAK, Janus kinase 1; TEAE, treatment emergent adverse event. Comparisons of AEs between the JAK1 inhibitor and dupilumab groups (p was calculated using Pearson's chi-square test or Fisher's exact test). Data missing: 1n=40, 2 n=32.

Files

Categories

Dermatology, Atopic Dermatitis

Licence